{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:32:06Z","timestamp":1782189126976,"version":"3.54.5"},"reference-count":126,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.intimp.2023.110524","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T16:31:52Z","timestamp":1688142712000},"page":"110524","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Biological effects of IL-33\/ST2 axis on oral diseases: autoimmune diseases and periodontal diseases"],"prefix":"10.1016","volume":"122","author":[{"given":"Mingfeng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingcen","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8612-4380","authenticated-orcid":false,"given":"Zhe","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2023.110524_b0005","doi-asserted-by":"crossref","unstructured":"Cui H, You Y, Cheng GW, et al. Advanced materials and technologies for oral diseases. Science and Technology of Advanced Materials. Dec 2023;24(1)2156257. 10.1080\/14686996.2022.2156257.","DOI":"10.1080\/14686996.2022.2156257"},{"key":"10.1016\/j.intimp.2023.110524_b0010","first-page":"281","volume":"73","author":"Brandtzaeg","year":"1965","journal-title":"AUTOIMMUNITY AND PERIODONTAL DISEASE. Odontol Tidskr."},{"issue":"6","key":"10.1016\/j.intimp.2023.110524_b0015","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41584-021-00605-2","article-title":"Epithelial-immune cell interplay in primary Sjogren syndrome salivary gland pathogenesis","volume":"17","author":"Verstappen","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110524_b0020","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3233\/CBM-181309","article-title":"Investigation of IL-33 serum levels in patients with benign and malignant salivary gland tumors","volume":"23","author":"Zare","year":"2018","journal-title":"Cancer Biomark."},{"key":"10.1016\/j.intimp.2023.110524_b0025","doi-asserted-by":"crossref","unstructured":"Cingu AK, Turkcu FM, Aktas S, Sahin A, Ayyildiz O. Serum IL-4, IL-12, IL-13, IL-27, and IL-33 levels in active and inactive ocular Behcet\u2019s disease. International Ophthalmology. 2020\/12\/01 2020;40(12):3441-3451. 10.1007\/s10792-020-01530-1.","DOI":"10.1007\/s10792-020-01530-1"},{"issue":"1","key":"10.1016\/j.intimp.2023.110524_b0030","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cyto.2013.07.006","article-title":"Potential contribution of interleukin-33 to the development of interstitial lung disease in patients with primary Sjogren\u2019s Syndrome","volume":"64","author":"Zhao","year":"2013","journal-title":"Cytokine"},{"issue":"4","key":"10.1016\/j.intimp.2023.110524_b0035","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s40266-021-00838-6","article-title":"Therapeutic Recommendations for the management of older adult patients with sjogren's syndrome","volume":"38","author":"Retamozo","year":"2021","journal-title":"Drugs Aging"},{"key":"10.1016\/j.intimp.2023.110524_b0040","doi-asserted-by":"crossref","unstructured":"Napenas JJ, Rouleau TS. Oral Complications of Sjogren's Syndrome. Oral and Maxillofacial Surgery Clinics of North America. Feb 2014;26(1):55-+. 10.1016\/j.coms.2013.09.004.","DOI":"10.1016\/j.coms.2013.09.004"},{"issue":"7","key":"10.1016\/j.intimp.2023.110524_b0045","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1007\/s10067-018-4153-8","article-title":"Advances in the diagnosis and treatment of Sjogren\u2019s syndrome","volume":"37","author":"Chen","year":"2018","journal-title":"Clin. Rheumatol."},{"issue":"8","key":"10.1016\/j.intimp.2023.110524_b0050","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s00296-018-4063-8","article-title":"Smoking, disease characteristics and serum cytokine levels in patients with primary Sj\u00f6gren\u2019s syndrome","volume":"38","author":"Olsson","year":"2018","journal-title":"Rheumatol. Int."},{"issue":"2","key":"10.1016\/j.intimp.2023.110524_b0055","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/rheumatology\/ket349","article-title":"Systemic involvement in primary Sjogren's syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry)","volume":"53","author":"Ramos-Casals","year":"2014","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.intimp.2023.110524_b0060","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1080\/17843286.2017.1314241","article-title":"Investigating the role of IL-33 in the pathogenesis of Behcet's Disease","volume":"72","author":"Cerci","year":"2017","journal-title":"Acta Clin. Belg."},{"issue":"12","key":"10.1016\/j.intimp.2023.110524_b0065","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1007\/s10792-020-01530-1","article-title":"Serum IL-4, IL-12, IL-13, IL-27, and IL-33 levels in active and inactive ocular Behcet's disease","volume":"40","author":"Cingu","year":"2020","journal-title":"Int. Ophthalmol."},{"key":"10.1016\/j.intimp.2023.110524_b0070","doi-asserted-by":"crossref","unstructured":"Zajac H, Turno-Krecicka A. Ocular Manifestations of Behcet's Disease: An Update on Diagnostic Challenges and Disease Management. Journal of Clinical Medicine. Nov 2021;10(21)5174. 10.3390\/jcm10215174.","DOI":"10.3390\/jcm10215174"},{"issue":"9","key":"10.1016\/j.intimp.2023.110524_b0075","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1111\/jcpe.13506","article-title":"Global, regional, and national burden of severe periodontitis, 1990\u20132019: an analysis of the Global Burden of Disease Study 2019","volume":"48","author":"Chen","year":"2021","journal-title":"J. Clin. Periodontol."},{"key":"10.1016\/j.intimp.2023.110524_b0080","doi-asserted-by":"crossref","unstructured":"He LF, Liu LJ, Li T, et al. Exploring the Imbalance of Periodontitis Immune System From the Cellular to Molecular Level. Frontiers in Genetics. Mar 2021;12653209. 10.3389\/fgene.2021.653209.","DOI":"10.3389\/fgene.2021.653209"},{"issue":"21","key":"10.1016\/j.intimp.2023.110524_b0085","doi-asserted-by":"crossref","first-page":"13242","DOI":"10.3390\/ijms232113242","article-title":"Mast cell cytokines in acute and chronic gingival tissue inflammation: role of IL-33 and IL-37","volume":"23","author":"Trimarchi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2023.110524_b0090","unstructured":"Curcic IB, Kizivat T, Petrovic A, et al. Therapeutic Perspectives of IL1 Family Members in Liver Diseases: An Update. Journal of Clinical and Translational Hepatology. Nov-Dec 2022;10(6):1186-1193. 10.14218\/jcth.2021.00501."},{"key":"10.1016\/j.intimp.2023.110524_b0095","doi-asserted-by":"crossref","unstructured":"Widjaja AA, Chothani S, Viswanathan S, Goh JWT, Lim WW, Cook SA. IL11 Stimulates IL33 Expression and Proinflammatory Fibroblast Activation across Tissues. International Journal of Molecular Sciences. Aug 2022;23(16)8900. 10.3390\/ijms23168900.","DOI":"10.3390\/ijms23168900"},{"key":"10.1016\/j.intimp.2023.110524_b0100","doi-asserted-by":"crossref","unstructured":"Shakerian L, Kolahdooz H, Garousi M, et al. IL-33\/ST2 axis in autoimmune disease. Cytokine. 2022\/10\/01\/ 2022;158:156015. 10.1016\/j.cyto.2022.156015.","DOI":"10.1016\/j.cyto.2022.156015"},{"issue":"5","key":"10.1016\/j.intimp.2023.110524_b0105","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.immuni.2005.09.015","article-title":"IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines","volume":"23","author":"Schmitz","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2023.110524_b0110","doi-asserted-by":"crossref","unstructured":"Alvarez F, Fritz JH, Piccirillo CA. Pleiotropic Effects of IL-33 on CD4+ T Cell Differentiation and Effector Functions. Systematic Review. Frontiers in Immunology. 2019-March-20 2019;1010.3389\/fimmu.2019.00522.","DOI":"10.3389\/fimmu.2019.00522"},{"key":"10.1016\/j.intimp.2023.110524_b0115","doi-asserted-by":"crossref","unstructured":"Fournie JJ, Poupot M. The Pro-tumorigenic IL-33 Involved in Antitumor Immunity: A Yin and Yang Cytokine. Frontiers in Immunology. Oct 2018;92506. 10.3389\/fimmu.2018.02506.","DOI":"10.3389\/fimmu.2018.02506"},{"key":"10.1016\/j.intimp.2023.110524_b0120","doi-asserted-by":"crossref","unstructured":"Shakerian L, Kolahdooz H, Garousi M, et al. IL-33\/ST2 axis in autoimmune disease. Cytokine. Oct 2022;158156015. 10.1016\/j.cyto.2022.156015.","DOI":"10.1016\/j.cyto.2022.156015"},{"issue":"4","key":"10.1016\/j.intimp.2023.110524_b0125","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.4049\/jimmunol.1003080","article-title":"The Dual Function Cytokine IL-33 Interacts with the transcription factor NF-kappa B To dampen NF-kappa B-stimulated gene transcription","volume":"187","author":"Ali","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2023.110524_b0130","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.archoralbio.2016.08.021","article-title":"Expression of IL-6, IL-10, IL-17 and IL-33 in the peri-implant crevicular fluid of patients with peri-implant mucositis and peri-implantitis","volume":"72","author":"Severino","year":"2016","journal-title":"Arch. Oral Biol."},{"issue":"6","key":"10.1016\/j.intimp.2023.110524_b0135","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1080\/17843286.2017.1314241","article-title":"Investigating the role of IL-33 in the pathogenesis of Beh\u00e7et\u2019s Disease","volume":"72","author":"\u00c7er\u00e7i","year":"2017","journal-title":"Acta Clin. Belg."},{"key":"10.1016\/j.intimp.2023.110524_b0140","doi-asserted-by":"crossref","unstructured":"Dong X, Feng J, Wen J, Bai D, Xu H. Effect of interleukin-33 on cementoblast-mediated cementum repair during orthodontic tooth movement. Archives of Oral Biology. 2020\/04\/01\/ 2020;112:104663. 10.1016\/j.archoralbio.2020.104663.","DOI":"10.1016\/j.archoralbio.2020.104663"},{"issue":"1","key":"10.1016\/j.intimp.2023.110524_b0145","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/imr.12619","article-title":"Interleukin-33 (IL-33): A nuclear cytokine from the IL-1 family","volume":"281","author":"Cayrol","year":"2018","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.intimp.2023.110524_b0150","doi-asserted-by":"crossref","unstructured":"Griesenauer B, Paczesny S. The ST2\/IL-33 Axis in Immune Cells during Inflammatory Diseases. Review. Frontiers in Immunology. 2017-April-24 2017;810.3389\/fimmu.2017.00475.","DOI":"10.3389\/fimmu.2017.00475"},{"issue":"2","key":"10.1016\/j.intimp.2023.110524_b0155","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0014-5793(89)81679-5","article-title":"A putative protein of a growth specific cDNA from BALB\/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor","volume":"258","author":"Tominaga","year":"1989","journal-title":"FEBS Lett."},{"issue":"2","key":"10.1016\/j.intimp.2023.110524_b0160","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.cyto.2012.06.286","article-title":"Interleukin-33 acts as a pro-inflammatory cytokine and modulates its receptor gene expression in highly metastatic human pancreatic carcinoma cells","volume":"60","author":"Schmieder","year":"2012","journal-title":"Cytokine"},{"key":"10.1016\/j.intimp.2023.110524_b0165","doi-asserted-by":"crossref","unstructured":"Fields JK, Kihn K, Birkedal GS, et al. Molecular Basis of Selective Cytokine Signaling Inhibition by Antibodies Targeting a Shared Receptor. Frontiers in Immunology. Dec 2021;12779100. 10.3389\/fimmu.2021.779100.","DOI":"10.1101\/2021.05.07.443154"},{"key":"10.1016\/j.intimp.2023.110524_b0170","doi-asserted-by":"crossref","unstructured":"Xu H, Sun L, He Y, et al. Deficiency in IL-33\/ST2 Axis Reshapes Mitochondrial Metabolism in Lipopolysaccharide-Stimulated Macrophages. Original Research. Frontiers in Immunology. 2019-February-01 2019;1010.3389\/fimmu.2019.00127.","DOI":"10.3389\/fimmu.2019.00127"},{"issue":"1","key":"10.1016\/j.intimp.2023.110524_b0175","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12933-021-01244-3","article-title":"Prognostic value of soluble suppression of tumorigenesis-2 (sST2) for cardiovascular events in coronary artery disease patients with and without diabetes mellitus","volume":"20","author":"Li","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"issue":"6","key":"10.1016\/j.intimp.2023.110524_b0180","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.immuni.2015.06.006","article-title":"Interleukin-33 in tissue homeostasis, injury, and inflammation","volume":"42","author":"Molofsky Ari","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2023.110524_b0185","doi-asserted-by":"crossref","unstructured":"Park JH, Ameri AH, Dempsey KE, et al. Nuclear IL-33\/SMAD signaling axis promotes cancer development in chronic inflammation. The EMBO Journal. 2021;40(7):e106151. 10.15252\/embj.2020106151.","DOI":"10.15252\/embj.2020106151"},{"key":"10.1016\/j.intimp.2023.110524_b0190","doi-asserted-by":"crossref","unstructured":"Cordero da Luz FA, Lima Oliveira AP, Borges D, Cristina Br\u00edgido P, Barbosa Silva MJ. The Physiopathological Role of IL-33: New Highlights in Bone Biology and a Proposed Role in Periodontal Disease. Mediators of Inflammation. 2014\/02\/18 2014;2014:342410. 10.1155\/2014\/342410.","DOI":"10.1155\/2014\/342410"},{"key":"10.1016\/j.intimp.2023.110524_b0195","doi-asserted-by":"crossref","unstructured":"Guo H, Bossila EA, Ma XR, Zhao CX, Zhao Y. Dual Immune Regulatory Roles of Interleukin-33 in Pathological Conditions. Cells. Oct 2022;11(20)3237. 10.3390\/cells11203237.","DOI":"10.3390\/cells11203237"},{"key":"10.1016\/j.intimp.2023.110524_b0200","doi-asserted-by":"crossref","unstructured":"Soyfoo MS, Nicaise C. Pathophysiologic role of Interleukin-33\/ST2 in Sj\u00f6gren's syndrome. Autoimmunity Reviews. 2021\/03\/01\/ 2021;20(3):102756. 10.1016\/j.autrev.2021.102756.","DOI":"10.1016\/j.autrev.2021.102756"},{"key":"10.1016\/j.intimp.2023.110524_b0205","unstructured":"Dandan Z, Shen C, Liu XM, Liu T, Ou YR, Ouyang RY. IL-33\/ST2 mediating systemic inflammation and neuroinflammation through NF-kB participated in the neurocognitive impairment in obstructive sleep apnea. International Immunopharmacology. Feb 2023;115109604. 10.1016\/j.intimp.2022.109604."},{"issue":"2","key":"10.1016\/j.intimp.2023.110524_b0210","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nri2692","article-title":"Disease-associated functions of IL-33: the new kid in the IL-1 family","volume":"10","author":"Liew","year":"2010","journal-title":"Nat. Rev. Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2023.110524_b0215","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nri.2016.95","article-title":"Interleukin-33 in health and disease","volume":"16","author":"Liew","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2023.110524_b0220","doi-asserted-by":"crossref","unstructured":"Larsen KM, Minaya MK, Vaish V, Pena MMO. The Role of IL-33\/ST2 Pathway in Tumorigenesis. International Journal of Molecular Sciences. Sep 2018;19(9)2676. 10.3390\/ijms19092676.","DOI":"10.3390\/ijms19092676"},{"key":"10.1016\/j.intimp.2023.110524_b0225","doi-asserted-by":"crossref","unstructured":"Awasthi V, Vilekar P, Rao G, Awasthi S. Anti-inflammatory mediators ST2 and SIGIRR are induced by diphenyldifluoroketone EF24 in lipopolysaccharide-stimulated dendritic cells. Immunobiology. Mar 2020;225(2)151886. 10.1016\/j.imbio.2019.11.021.","DOI":"10.1016\/j.imbio.2019.11.021"},{"key":"10.1016\/j.intimp.2023.110524_b0230","doi-asserted-by":"crossref","unstructured":"Gunther S, Deredge D, Bowers AL, et al. IL-1 Family Cytokines Use Distinct Molecular Mechanisms to Signal through Their Shared Co-receptor. Immunity. Sep 2017;47(3):510-+. 10.1016\/j.immuni.2017.08.004.","DOI":"10.1016\/j.immuni.2017.08.004"},{"issue":"5","key":"10.1016\/j.intimp.2023.110524_b0235","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jcjd.2018.01.008","article-title":"Activated mast cells mediate low-grade inflammation in Type 2 diabetes: interleukin-37 could be beneficial","volume":"42","author":"Conti","year":"2018","journal-title":"Can. J. Diabetes"},{"issue":"12","key":"10.1016\/j.intimp.2023.110524_b0240","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.3390\/ijms21124297","article-title":"Advances in mast cell activation by IL-1 and IL-33 in Sj\u00f6gren\u2019s Syndrome: promising inhibitory effect of IL-37","volume":"21","author":"Conti","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2023.110524_b0245","doi-asserted-by":"crossref","unstructured":"Rizzo C, La Barbera L, Lo Pizzo M, Ciccia F, Sireci G, Guggino G. Invariant NKT Cells and Rheumatic Disease: Focus on Primary Sjogren Syndrome. International Journal of Molecular Sciences. Nov 2019;20(21)5435. 10.3390\/ijms20215435.","DOI":"10.3390\/ijms20215435"},{"issue":"1","key":"10.1016\/j.intimp.2023.110524_b0250","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.immuni.2015.06.021","article-title":"An Interleukin-33-Mast Cell-Interleukin-2 Axis Suppresses Papain-Induced Allergic Inflammation by Promoting Regulatory T Cell Numbers","volume":"43","author":"Morita","year":"2015","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.intimp.2023.110524_b0255","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/imcb.12200","article-title":"IL-33 regulates cytokine production and neutrophil recruitment via the p38 MAPK-activated kinases MK2\/3","volume":"97","author":"McCarthy","year":"2019","journal-title":"Immunol. Cell Biol."},{"issue":"12","key":"10.1016\/j.intimp.2023.110524_b0260","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.4049\/jimmunol.2101070","article-title":"The IL-33\/ST2 Axis promotes primary sjogren's syndrome by enhancing salivary epithelial cell activation and type 1 immune response","volume":"208","author":"Dong","year":"2022","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2023.110524_b0265","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1136\/annrheumdis-2015-208557","article-title":"Pitfalls for detecting interleukin-33 by ELISA in the serum of patients with primary Sjogren syndrome: comparison of different kits","volume":"75","author":"Riviere","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2023.110524_b0270","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cyto.2013.07.006","article-title":"Potential contribution of interleukin-33 to the development of interstitial lung disease in patients with primary Sjogren's Syndrome","volume":"64","author":"Zhao","year":"2013","journal-title":"Cytokine"},{"issue":"2","key":"10.1016\/j.intimp.2023.110524_b0275","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3899\/jrheum.140234","article-title":"The Interleukin 33\/ST2 Axis in patients with primary sjogren syndrome: expression in serum and salivary glands, and the clinical association","volume":"42","author":"Jung","year":"2015","journal-title":"J. Rheumatol."},{"issue":"7","key":"10.1016\/j.intimp.2023.110524_b0280","first-page":"1295","article-title":"The IL33\/ST2 axis in Sjogren syndrome in relation to disease activity","volume":"20","author":"Margiotta","year":"2016","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2023.110524_b0285","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1136\/archdischild-2015-308255","article-title":"Variation in paediatric hospital antibiotic guidelines in Europe","volume":"101","author":"Spyridis","year":"2016","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.intimp.2023.110524_b0290","doi-asserted-by":"crossref","unstructured":"Soyfoo MS, Nicaise C. Pathophysiologic role of Interleukin-33\/ST2 in Sjogren's syndrome. Autoimmunity Reviews. Mar 2021;20(3)102756. 10.1016\/j.autrev.2021.102756.","DOI":"10.1016\/j.autrev.2021.102756"},{"issue":"6","key":"10.1016\/j.intimp.2023.110524_b0295","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1136\/annrheumdis-2012-203187","article-title":"Potential involvement of the IL-33-ST2 axis in the pathogenesis of primary Sjogren's syndrome","volume":"73","author":"Awada","year":"2014","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.intimp.2023.110524_b0300","first-page":"428","article-title":"Serum levels of soluble ST2 and interleukin-33 in patients with dermatomyositis and polymyositis","volume":"31","author":"Yuan","year":"2013","journal-title":"Clin. Exp. Rheumatol.. May-Jun"},{"issue":"2","key":"10.1016\/j.intimp.2023.110524_b0305","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.cyto.2013.03.007","article-title":"Soluble ST2 as a marker of disease activity in systemic juvenile idiopathic arthritis","volume":"62","author":"Ishikawa","year":"2013","journal-title":"Cytokine"},{"issue":"4","key":"10.1016\/j.intimp.2023.110524_b0310","doi-asserted-by":"crossref","first-page":"309","DOI":"10.15644\/asc49\/4\/6","article-title":"The Effect of Tobacco Smoking on Salivation","volume":"49","author":"Petrusic","year":"2015","journal-title":"Acta Stomatol. Croat."},{"key":"10.1016\/j.intimp.2023.110524_b0315","doi-asserted-by":"crossref","unstructured":"Li Z, Fu T, Dong C, Li L, Gu Z. SERUM LEVELS OF INTERLEUKIN-33 ARE ASSOCIATED WITH DEPRESSIVE SYMPTOMS IN PATIENTS WITH PRIMARY SJOGREN'S SYNDROME. Annals of the Rheumatic Diseases. Jun 2018;77:1277-1277. 10.1136\/annrheumdis-2018-eular.6110.","DOI":"10.1136\/annrheumdis-2018-eular.6110"},{"key":"10.1016\/j.intimp.2023.110524_b0320","doi-asserted-by":"crossref","unstructured":"Tong BN, Liu XL, Xiao J, Su GF. Immunopathogenesis of Behcet's Disease. Frontiers in Immunology. Mar 2019;10665. 10.3389\/fimmu.2019.00665.","DOI":"10.3389\/fimmu.2019.00665"},{"key":"10.1016\/j.intimp.2023.110524_b0325","doi-asserted-by":"crossref","unstructured":"Yang YX, Zhang YJ, Chen X, Su Z, Deng Y, Zhao Q. Khasianine ameliorates psoriasis-like skin inflammation and represses TNF-alpha\/NF-kappa B axis mediated transactivation of IL-17A and IL-33 in keratinocytes. Journal of Ethnopharmacology. Jun 2022;292115124. 10.1016\/j.jep.2022.115124.","DOI":"10.1016\/j.jep.2022.115124"},{"key":"10.1016\/j.intimp.2023.110524_b0330","doi-asserted-by":"crossref","unstructured":"Cavalli G, Colafrancesco S, Emmi G, et al. Interleukin 1 alpha: a comprehensive review on the role of IL-1 alpha in the pathogenesis and treatment of autoimmune and inflammatory diseases. Autoimmunity Reviews. Mar 2021;20(3)102763. 10.1016\/j.autrev.2021.102763.","DOI":"10.1016\/j.autrev.2021.102763"},{"key":"10.1016\/j.intimp.2023.110524_b0335","first-page":"108108887","article-title":"IL-33 in autoimmunity; possible therapeutic target","author":"Yuan","year":"2022","journal-title":"Int. Immunopharmacol."},{"issue":"8","key":"10.1016\/j.intimp.2023.110524_b0340","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.3346\/jkms.2013.28.8.1145","article-title":"Serum Level of Interleukin-33 and Soluble ST2 and their association with disease activity in patients with behcet's disease","volume":"28","author":"Kim","year":"2013","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.intimp.2023.110524_b0345","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.clim.2018.03.016","article-title":"Elevated expression of TSLP and IL-33 in Behget's disease skin lesions: IL-37 alleviate inflammatory effect of TSLP","volume":"192","author":"Kacem","year":"2018","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.intimp.2023.110524_b0350","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.imlet.2018.11.005","article-title":"Interleukin-33 gene expression and rs1342326 polymorphism in Behcet's disease","volume":"212","author":"Talei","year":"2019","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.intimp.2023.110524_b0355","first-page":"114109479","article-title":"IL-33\/ST2 axis promotes remodeling of the extracellular matrix and drives protective microglial responses in the mouse model of perioperative neurocognitive disorders","author":"Li","year":"2023","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110524_b0360","doi-asserted-by":"crossref","first-page":"159-+","DOI":"10.1016\/j.immuni.2021.12.001","article-title":"Disruption of the IL-33-ST2-AKT signaling axis impairs neurodevelopment by inhibiting microglial metabolic adaptation and phagocytic function","volume":"55","author":"He","year":"2022","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.intimp.2023.110524_b0365","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/cmi.2014.31","article-title":"Increased interleukin 33 in patients with neuro-Behcet's disease: correlation with MCP-1 and IP-10 chemokines","volume":"11","author":"Hamzaoui","year":"2014","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.intimp.2023.110524_b0370","doi-asserted-by":"crossref","unstructured":"Pei MH, Liu XS, Yang PZ, et al. Genetic Association of Interleukin 33\/ST2 Polymorphisms With Behcet's Uveitis. Frontiers in Immunology. Mar 2021;12589639. 10.3389\/fimmu.2021.589639.","DOI":"10.3389\/fimmu.2021.589639"},{"issue":"2","key":"10.1016\/j.intimp.2023.110524_b0375","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10238-010-0115-4","article-title":"Association of increased serum IL-33 levels with clinical and laboratory characteristics of systemic lupus erythematosus in Chinese population","volume":"11","author":"Yang","year":"2011","journal-title":"Clin. Exp. Med."},{"issue":"3","key":"10.1016\/j.intimp.2023.110524_b0380","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00296-014-3111-2","article-title":"Serum IL-33 level and IL-33 gene polymorphisms in Behcet's disease","volume":"35","author":"Koca","year":"2015","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.intimp.2023.110524_b0385","first-page":"8739489","article-title":"IL-33 in Rheumatic Diseases","author":"Dong","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.intimp.2023.110524_b0390","doi-asserted-by":"crossref","unstructured":"Koca SS, Donder E, Deniz F, Ozgen M, Ilhan N, Isik A. SERUM IL-33 LEVEL IN BEHCET'S DISEASE AND RHEUMATOID ARTHRITIS. Annals of the Rheumatic Diseases. Jun 2013;71:232-232. 10.1136\/annrheumdis-2012-eular.2193.","DOI":"10.1136\/annrheumdis-2012-eular.2193"},{"issue":"4","key":"10.1016\/j.intimp.2023.110524_b0395","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1080\/08820139.2021.1878212","article-title":"The Role of the IL-33\/ST2 immune pathway in autoimmunity: new insights and perspectives","volume":"51","author":"Ramezani","year":"2022","journal-title":"Immunol. Invest."},{"issue":"24","key":"10.1016\/j.intimp.2023.110524_b0400","doi-asserted-by":"crossref","first-page":"13288","DOI":"10.3390\/ijms222413288","article-title":"The Paradigm Change of IL-33 in Vascular Biology","volume":"22","author":"Demyanets","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2023.110524_b0405","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1186\/s12903-022-02530-6","article-title":"Advances in novel therapeutic approaches for periodontal diseases. Bmc","volume":"22","author":"Haque","year":"2022","journal-title":"Oral Health"},{"key":"10.1016\/j.intimp.2023.110524_b0410","unstructured":"Kedlaya MN, Puzhankara L, Prasad R, Raj A. Periodontal Disease Pathogens, Pathogenesis, and Therapeutics: The CRISPR-Cas Effect. Crispr Journal. 10.1089\/crispr.2022.0094."},{"issue":"1","key":"10.1016\/j.intimp.2023.110524_b0415","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3390\/ijms23010372","article-title":"Pyroptosis-mediated periodontal disease","volume":"23","author":"Sordi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.intimp.2023.110524_b0420","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1002\/JPER.21-0587","article-title":"The neutrophil elastase-upregulated placenta growth factor promotes the pathogenesis and progression of periodontal disease","volume":"93","author":"Tseng","year":"2022","journal-title":"J. Periodontol."},{"issue":"2","key":"10.1016\/j.intimp.2023.110524_b0425","doi-asserted-by":"crossref","first-page":"695","DOI":"10.3390\/ijms22020695","article-title":"Elevated Expression of Cathepsin K in periodontal ligament fibroblast by inflammatory cytokines accelerates osteoclastogenesis via paracrine mechanism in periodontal disease","volume":"22","author":"Heo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.intimp.2023.110524_b0430","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1084\/jem.20071868","article-title":"IL-33 reduces the development of atherosclerosis","volume":"205","author":"Miller","year":"2008","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.intimp.2023.110524_b0435","first-page":"179","article-title":"Evaluating Serum Levels of IL-33, IL-36, IL-37 and Gene expression of IL-37 in patients with psoriasis vulgaris","volume":"17","author":"Sehat","year":"2018","journal-title":"Iran. J. Allergy Asthma Immunol."},{"key":"10.1016\/j.intimp.2023.110524_b0440","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-47620-8","article-title":"The interleukin-33-mediated inhibition of expression of two key genes implicated in atherosclerosis in human macrophages requires MAP kinase, phosphoinositide 3-kinase and nuclear factor-kappa B signaling pathways","author":"Buckley","year":"2019","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.intimp.2023.110524_b0445","first-page":"385","article-title":"Saliva, Serum Levels of Interleukin-21,-33 and Prostaglandin E2 in patients with generalised aggressive or chronic periodontitis","volume":"15","author":"Gumus","year":"2017","journal-title":"Oral Health Prev. Dent."},{"issue":"3","key":"10.1016\/j.intimp.2023.110524_b0450","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1902\/jop.2011.110239","article-title":"Interleukin-33 Levels in gingival crevicular fluid, saliva, or plasma do not differentiate chronic periodontitis","volume":"83","author":"Buduneli","year":"2012","journal-title":"J. Periodontol."},{"issue":"2","key":"10.1016\/j.intimp.2023.110524_b0455","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s10266-016-0259-0","article-title":"Increased levels of interleukin-33 in gingival crevicular fluids of patients with chronic periodontitis","volume":"105","author":"Saglam","year":"2017","journal-title":"Odontology"},{"issue":"2","key":"10.1016\/j.intimp.2023.110524_b0460","first-page":"208","article-title":"Immunological signatures in saliva of systemic lupus erythematosus patients: influence of periodontal condition","volume":"37","author":"Mendonca","year":"2019","journal-title":"Clin. Exp. Rheumatol.. Mar-Apr"},{"issue":"4","key":"10.1016\/j.intimp.2023.110524_b0465","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/jre.12235","article-title":"Interleukin-33 could play an important role in the pathogenesis of periodontitis","volume":"50","author":"Koseoglu","year":"2015","journal-title":"J. Periodontal Res."},{"issue":"3","key":"10.1016\/j.intimp.2023.110524_b0470","doi-asserted-by":"crossref","first-page":"e0283179","DOI":"10.1371\/journal.pone.0283179","article-title":"Single nucleotide variants in the IL33 and IL1RL1 (ST2) genes are associated with periodontitis and with Aggregatibacter actinomycetemcomitans in the dental plaque biofilm: a putative role in understanding the host immune response in periodontitis","volume":"18","author":"Trindade","year":"2023","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.intimp.2023.110524_b0475","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1016\/j.ajpath.2015.08.013","article-title":"Osteoprotective effects of IL-33\/ST2 Link to Osteociast Apoptosis","volume":"185","author":"Lima","year":"2015","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.intimp.2023.110524_b0480","first-page":"1130","article-title":"The cytokine network involved in the host immune response to periodontitis. International","author":"Pan","year":"2019","journal-title":"J. Oral Sci."},{"key":"10.1016\/j.intimp.2023.110524_b0485","doi-asserted-by":"crossref","unstructured":"Papathanasiou E, Conti P, Carinci F, Lauritano D, Theoharides TC. IL-1 Superfamily Members and Periodontal Diseases. Journal of Dental Research. Dec 2020;99(13):1425-1434. 0022034520945209. 10.1177\/0022034520945209.","DOI":"10.1177\/0022034520945209"},{"issue":"3","key":"10.1016\/j.intimp.2023.110524_b0490","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/imm.13386","article-title":"ATP\/IL-33-triggered hyperactivation of mast cells results in an amplified production of pro-inflammatory cytokines and eicosanoids","volume":"164","author":"Jordan","year":"2021","journal-title":"Immunology"},{"key":"10.1016\/j.intimp.2023.110524_b0495","doi-asserted-by":"crossref","unstructured":"Tada H, Matsuyama T, Nishioka T, et al. Porphyromonas gingivalis Gingipain-Dependently Enhances IL-33 Production in Human Gingival Epithelial Cells. Plos One. Apr 2016;11(4)e0152794. 10.1371\/journal.pone.0152794.","DOI":"10.1371\/journal.pone.0152794"},{"issue":"3","key":"10.1016\/j.intimp.2023.110524_b0500","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2220\/biomedres.38.189","article-title":"Increases in IL-33 production by fimbriae and lipopeptide from Porphyromonas gingivalis in mouse bone marrow-derived dendritic cells via Toll-like receptor 2","volume":"38","author":"Tada","year":"2017","journal-title":"Biomed. Res.-Tokyo."},{"issue":"1","key":"10.1016\/j.intimp.2023.110524_b0505","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1146\/annurev.immunol.20.100301.064753","article-title":"RANK-L and RANK: T cells, bone loss, and mammalian evolution","volume":"20","author":"Theill","year":"2002","journal-title":"Annu. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110524_b0510","first-page":"244","article-title":"Modulating macrophage activities to promote endogenous bone regeneration: Biological mechanisms and engineering approaches","volume":"6","author":"Niu","year":"2021","journal-title":"Bioact. Mater."},{"issue":"7","key":"10.1016\/j.intimp.2023.110524_b0515","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1177\/0022034515577815","article-title":"IL-33 Exacerbates periodontal disease through induction of RANKL","volume":"94","author":"Malcolm","year":"2015","journal-title":"J. Dent. Res."},{"issue":"12","key":"10.1016\/j.intimp.2023.110524_b0520","doi-asserted-by":"crossref","first-page":"e0168080","DOI":"10.1371\/journal.pone.0168080","article-title":"Interleukin-33 and RANK-L interplay in the alveolar bone loss associated to periodontitis","volume":"11","author":"Laperine","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.intimp.2023.110524_b0525","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2220\/biomedres.44.9","article-title":"IL-33 deficiency suppresses alveolar bone loss in a ligature-induced periodontitis model","volume":"44","author":"Aida","year":"2023","journal-title":"Biomed. Res.-Tokyo."},{"issue":"7","key":"10.1016\/j.intimp.2023.110524_b0530","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1177\/0300060519854630","article-title":"Role of interleukin-33 in the clinical pathogenesis of chronic apical periodontitis","volume":"47","author":"Gegen","year":"2019","journal-title":"J. Int. Med. Res."},{"issue":"5","key":"10.1016\/j.intimp.2023.110524_b0535","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/jre.13039","article-title":"Inhibition of osteoclastogenesis by interleukin-33 administration in the periodontal ligament under mechanical loading","volume":"57","author":"Dong","year":"2022","journal-title":"J. Periodontal Res."},{"key":"10.1016\/j.intimp.2023.110524_b0540","doi-asserted-by":"crossref","unstructured":"Dong XM, Feng J, Wen J, Bai D, Xu H. Effect of interleukin-33 on cementoblast-mediated cementum repair during orthodontic tooth movement. Archives of Oral Biology. Apr 2020;112104663. 10.1016\/j.archoralbio.2020.104663.","DOI":"10.1016\/j.archoralbio.2020.104663"},{"key":"10.1016\/j.intimp.2023.110524_b0545","doi-asserted-by":"crossref","unstructured":"Wang LT, Chen LR, Chen KH. Hormone-Related and Drug-Induced Osteoporosis: A Cellular and Molecular Overview. International Journal of Molecular Sciences. Mar 2023;24(6)5814. 10.3390\/ijms24065814.","DOI":"10.3390\/ijms24065814"},{"issue":"6","key":"10.1016\/j.intimp.2023.110524_b0550","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1177\/0022034516633154","article-title":"Osteoprotective effects of estrogen in the maxillary bone depend on ER alpha","volume":"95","author":"Macari","year":"2016","journal-title":"J. Dent. Res."},{"issue":"10","key":"10.1016\/j.intimp.2023.110524_b0555","doi-asserted-by":"crossref","first-page":"8511","DOI":"10.1002\/jcb.27080","article-title":"ST2 regulates bone loss in a site-dependent and estrogen-dependent manner","volume":"119","author":"Macari","year":"2018","journal-title":"J. Cell. Biochem."},{"issue":"3","key":"10.1016\/j.intimp.2023.110524_b0560","first-page":"270","volume":"56","author":"Louisy","year":"2022"},{"issue":"1","key":"10.1016\/j.intimp.2023.110524_b0565","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1159\/000492885","article-title":"Therapeutic strategies for targeting IL-33\/ST2 signalling for the treatment of inflammatory diseases","volume":"49","author":"Chen","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"issue":"8","key":"10.1016\/j.intimp.2023.110524_b0570","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1002\/eji.202149175","article-title":"IL-33\/ST2 as a potential target for tumor immunotherapy","volume":"51","author":"Jiang","year":"2021","journal-title":"Eur. J. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2023.110524_b0575","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/thoraxjnl-2016-208772","article-title":"The role of interleukin-33 in chronic rhinosinusitis","volume":"72","author":"Kim","year":"2017","journal-title":"Thorax"},{"issue":"36","key":"10.1016\/j.intimp.2023.110524_b0580","doi-asserted-by":"crossref","first-page":"26369","DOI":"10.1074\/jbc.M704916200","article-title":"Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation","volume":"282","author":"Hayakawa","year":"2007","journal-title":"J Biol Chem."},{"issue":"1","key":"10.1016\/j.intimp.2023.110524_b0585","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jdermsci.2019.08.006","article-title":"Interleukin-33 in atopic dermatitis","volume":"96","author":"Imai","year":"2019","journal-title":"J. Dermatol. Sci."},{"issue":"8","key":"10.1016\/j.intimp.2023.110524_b0590","doi-asserted-by":"crossref","first-page":"e11944","DOI":"10.1371\/journal.pone.0011944","article-title":"IL-33 Is produced by mast cells and regulates IgE-dependent inflammation","volume":"5","author":"Hsu","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2023.110524_b0595","article-title":"Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis","volume":"11(515)eaax2945","author":"Chen","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.intimp.2023.110524_b0600","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jaci.2019.02.028","article-title":"IL-33trap is a novel IL-33-neutralizing biologic that inhibits allergic airway inflammation","volume":"144","author":"Holgado","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2023.110524_b0605","doi-asserted-by":"crossref","first-page":"1624-+","DOI":"10.1016\/j.jaci.2019.08.039","article-title":"IL-33 blockade affects mediators of persistence and exacerbation in a model of chronic airway inflammation","volume":"144","author":"Allinne","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"issue":"18","key":"10.1016\/j.intimp.2023.110524_b0610","doi-asserted-by":"crossref","first-page":"6953","DOI":"10.3390\/ijms21186953","article-title":"Blocking of the IL-33\/ST2 Signaling Axis by a Single-Chain Antibody Variable Fragment (scFv) Specific to IL-33 with a Defined Epitope","volume":"21","author":"Park","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2023.110524_b0615","doi-asserted-by":"crossref","unstructured":"Lin J, Zhang LL, Zhao GQ, et al. A Novel Interleukin 33\/ST2 Signaling Regulates Inflammatory Response in Human Corneal Epithelium. Plos One. Apr 2013;8(4)e60963. 10.1371\/journal.pone.0060963.","DOI":"10.1371\/journal.pone.0060963"},{"issue":"1","key":"10.1016\/j.intimp.2023.110524_b0620","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s11658-018-0117-x","article-title":"Elevated IL-33 promotes expression of MMP2 and MMP9 via activating STAT3 in alveolar macrophages during LPS-induced acute lung injury","volume":"23","author":"Liang","year":"2018","journal-title":"Cell. Mol. Biol. Lett."},{"issue":"5","key":"10.1016\/j.intimp.2023.110524_b0625","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/s41416-022-02090-0","article-title":"IL-33\/ST2 signaling promotes constitutive and inductive PD-L1 expression and immune escape in oral squamous cell carcinoma","volume":"128","author":"Zhao","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.intimp.2023.110524_b0630","doi-asserted-by":"crossref","unstructured":"Shen J-X, Liu J, Zhang G-J. Interleukin-33 in Malignancies: Friends or Foes? Review. Frontiers in Immunology. 2018-December-20 2018;910.3389\/fimmu.2018.03051.","DOI":"10.3389\/fimmu.2018.03051"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923008470?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923008470?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T14:14:17Z","timestamp":1736432057000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923008470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":126,"alternative-id":["S1567576923008470"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110524","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biological effects of IL-33\/ST2 axis on oral diseases: autoimmune diseases and periodontal diseases","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110524","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110524"}}